OPKO Health, Inc. (NASDAQ:OPK) Short Interest Down 14.0% in December

OPKO Health, Inc. (NASDAQ:OPK) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 84,800,000 shares, a decline of 14.0% from the November 30th total of 98,570,000 shares. Based on an average daily volume of 3,950,000 shares, the short-interest ratio is currently 21.5 days. Currently, 27.4% of the company’s shares are short sold.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 100,000 shares of the stock in a transaction dated Thursday, November 14th. The stock was purchased at an average price of $1.62 per share, with a total value of $162,000.00. Following the transaction, the chief executive officer now owns 211,612,405 shares of the company’s stock, valued at approximately $342,812,096.10. This trade represents a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have bought a total of 1,304,255 shares of company stock valued at $2,024,605 over the last quarter. 47.26% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On OPKO Health

Hedge funds have recently modified their holdings of the stock. World Investment Advisors LLC acquired a new position in shares of OPKO Health in the third quarter valued at about $61,000. Virtu Financial LLC acquired a new position in OPKO Health in the 3rd quarter worth approximately $120,000. Barclays PLC raised its position in OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after buying an additional 329,870 shares during the last quarter. Orion Portfolio Solutions LLC acquired a new stake in OPKO Health during the 3rd quarter valued at approximately $45,000. Finally, XTX Topco Ltd lifted its stake in OPKO Health by 166.5% during the 3rd quarter. XTX Topco Ltd now owns 108,652 shares of the biotechnology company’s stock valued at $162,000 after acquiring an additional 67,883 shares during the period. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Stock Up 0.7 %

Shares of OPKO Health stock traded up $0.01 during trading on Tuesday, reaching $1.48. The company’s stock had a trading volume of 1,419,928 shares, compared to its average volume of 6,655,674. OPKO Health has a 1-year low of $0.85 and a 1-year high of $1.76. The company has a 50-day simple moving average of $1.55 and a two-hundred day simple moving average of $1.49. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -7.79 and a beta of 1.62.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on OPK. Barrington Research reiterated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th. StockNews.com lowered OPKO Health from a “hold” rating to a “sell” rating in a research note on Thursday, December 26th. Piper Sandler reiterated an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a report on Thursday, September 26th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.